Tesamorelin

Mechanism

Evidence tier: 2 — GHRH receptor pharmacology characterized in human trials; downstream visceral adipose tissue reduction is directly measured by CT/MRI in registration program.

Tesamorelin is a synthetic 44-amino-acid GHRH analog stabilized against rapid proteolytic degradation by a trans-3-hexenoyl modification of the N-terminus. The stabilization extends serum half-life relative to the native GHRH 1-44 peptide and enables once-daily subcutaneous dosing. Mechanistically, tesamorelin binds the GHRH receptor on anterior pituitary somatotrophs and stimulates pulsatile endogenous GH release, with subsequent hepatic IGF-1 elevation. The physiologic preservation of pulsatility plus somatostatin/IGF-1 negative-feedback regulation distinguishes tesamorelin from rhGH. The clinically distinctive effect — visceral adipose tissue (VAT) reduction without comparable subcutaneous fat loss — is well-characterized: Falutz 2007 (PMID 18057338) demonstrated approximately 15-20% VAT reduction over 26 weeks in HIV patients with abdominal fat accumulation, with preferential VAT (visceral) versus SAT (subcutaneous) effect. Stanley 2012 (PMID 22495074) showed VAT reduction correlated with measurable metabolic improvements — triglycerides, insulin sensitivity markers — confirming that the structural fat change tracks with downstream metabolic benefit rather than being a cosmetic-only effect.

Typical protocols

Evidence tier: 1 — FDA-labeled dosing for HIV indication is RCT-derived. Off-label non-HIV dosing follows the same schedule by convention.

The FDA-labeled dose (Egrifta SV) for HIV-associated visceral adipose excess is:

• Dose: 1.4 mg subcutaneously once daily (preferred — Egrifta SV reformulation) or 2 mg subcutaneously once daily (original Egrifta formulation)
• Route: Subcutaneous injection into abdomen; site rotation standard
• Timing: Most prescribers recommend bedtime to align with native nocturnal GH pulse, but daytime dosing is also acceptable
• Duration: 26-week minimum to demonstrate VAT reduction in trial data; continued use needed to maintain effect (VAT regains within ~6 months of discontinuation)
• Monitoring: IGF-1 at baseline and 13-26 weeks; clinical response (waist circumference, VAT imaging if available); fasting glucose given mild glycemic effects

Off-label use for non-HIV visceral fat or as a GLP-1 muscle-preservation adjunct follows the same dosing schedule by convention. Compounded tesamorelin sourced via 503A pharmacies is often dosed at 1-2 mg/day with the same route and timing. Cycle length in off-label contexts varies — 3-6 months is typical for body-composition use cases, with reassessment.

Evidence by indication

Evidence tier: 1 — HIV-VAT indication has Phase 3 RCTs and FDA approval. Non-HIV indications are smaller observational and mechanistic studies.

HIV-associated visceral adipose tissue reduction (FDA-approved): Falutz 2007 (PMID 18057338) is the landmark NEJM Phase 3 trial — 412 HIV patients with abdominal fat accumulation, randomized to tesamorelin 2 mg/day vs placebo for 26 weeks. The tesamorelin arm showed mean VAT reduction of 15.2% vs 5.0% gain with placebo (treatment difference ~20%). Triglycerides decreased; HDL improved; lean mass increased modestly. The Phase 3 extension and Stanley 2012 (PMID 22495074) demonstrated that VAT reduction correlated with the metabolic improvements, supporting the mechanism-to-outcome chain.

Non-HIV visceral adiposity: Stanley 2014 and subsequent observational work show similar VAT-preferential reduction in non-HIV cohorts with abdominal fat accumulation, though the FDA indication remains HIV-restricted. Effect sizes appear comparable to the HIV population.

Hepatic steatosis / NAFLD: Stanley and colleagues published HIV-NAFLD trials showing tesamorelin reduces hepatic fat fraction by MRS imaging, with concurrent improvements in liver enzymes. This is the strongest secondary indication evidence.

GLP-1 muscle-preservation adjunct: No RCT data. The mechanistic case — GHRH-mediated GH/IGF-1 elevation may support lean-mass synthesis during GLP-1 weight loss — is plausible. See GLP-1 muscle preservation for the full positioning.

Cognition (HIV cohorts): Small studies of tesamorelin in HIV-associated cognitive impairment showed signal on neurocognitive endpoints. Not validated outside this specific population.

Safety profile

Evidence tier: 1 — Multi-year pharmacovigilance from FDA-approved use plus extension trial data.

Common adverse events from the Phase 3 program: injection-site reactions (erythema, pain, pruritus), arthralgia, peripheral edema, myalgia, and headache. Most are mild and self-limiting. Glucose tolerance is the most clinically meaningful concern — tesamorelin produces a small increase in fasting glucose and HbA1c, consistent with GH-axis effects on insulin sensitivity. The effect is generally small and reversible but warrants monitoring in patients with prediabetes or established diabetes.

Contraindications per FDA label: active malignancy (the IGF-1 elevation contraindicates use in patients with active or recent cancer), disrupted hypothalamic-pituitary axis (post-hypophysectomy, pituitary tumor, pituitary surgery, head irradiation, head trauma), pregnancy, and hypersensitivity to tesamorelin or mannitol (formulation excipient). Diabetic retinopathy: use with caution and ophthalmology monitoring; GH-axis stimulation is a theoretical concern. WADA-prohibited; athletes should not use it.

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning across the GH-axis and visceral-fat-reduction landscape.

For visceral fat reduction specifically: tesamorelin has the strongest direct RCT evidence of any peptide. GLP-1s and tirzepatide produce VAT reduction as part of broader weight loss but are not VAT-selective — tesamorelin's preferential VAT effect (vs SAT) is its mechanistic differentiator.

For adult GH-axis support more broadly: sermorelin is the older, lower-cost option with longer clinical history but less direct VAT or metabolic-endpoint evidence. CJC-1295 + Ipamorelin is the convenience-dosing alternative with weaker direct evidence. Tesamorelin is the highest-evidence GHRH analog when the indication is visceral adiposity or metabolic syndrome features; sermorelin or CJC/Ipamorelin are reasonable when the indication is more general age-related GH decline at lower cost.

For GLP-1 lean-mass adjunct use: tesamorelin is the consensus choice over alternatives like AOD-9604, which has failed multiple Phase 2b trials in fat-loss endpoints. See GLP-1 muscle preservation.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content.

Tesamorelin is FDA-approved as Egrifta SV (Theratechnologies) for HIV-associated visceral adipose tissue reduction. Off-label use for non-HIV indications is at prescriber discretion. Branded Egrifta SV is high-cost ($3,000+/month) and typically reserved for the on-label HIV population. Compounded tesamorelin via 503A pharmacies is the cost-accessible pathway for off-label use, typically $300-500/month. Sermorelin and tesamorelin are on the FDA bulks list for 503A compounding and remain lawfully available. Access via prescriber + 503A pharmacy or telehealth partnership — see the clinic directory. WADA-prohibited; athletes should not use it.

References

• Falutz J, Allas S, Blot K, et al. 2007. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. N Engl J Med. PMID 18057338
• Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. 2012. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. PMID 22495074
• Walker RF. 2006. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. PMID 18046908
• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185

Limitations

Tesamorelin should not be used in patients with active or recent malignancy, disrupted hypothalamic-pituitary axis or post-pituitary-surgery patients without endocrinology workup, patients with diabetic retinopathy without ophthalmology supervision, pregnant or nursing patients, patients with uncontrolled type 2 diabetes (use with monitoring in controlled diabetes), patients with severe renal or hepatic impairment without specialist supervision, anyone subject to WADA testing, or patients with documented hypersensitivity to mannitol.

The cited evidence cannot tell us whether tesamorelin in non-HIV populations produces comparable long-term cardiometabolic benefit, whether the GLP-1 + tesamorelin combination preserves a clinically meaningful additional fraction of lean mass over GLP-1 + resistance training alone, what the right discontinuation strategy is for long-term users (VAT rebounds within ~6 months of stopping), or how the molecule performs in patients over 70. We would change our framing on publication of an RCT of GLP-1 + tesamorelin with DEXA endpoints, expansion of FDA labeling to non-HIV visceral fat, or any change to the tesamorelin 503A compounding status.